Such tools include prostate cancer antigen 3 (PCA3), circulating tumor cells (CTCs), extracellular vesicles (EVs), circulating tumor DNA (ctDNA) and RNA (ctRNA), and genetic biomarkers like TMPRSS:ERG gene fusions [52] (A detailed list of prostate cancer derived EV markers is provided in Table 1). This evidence concerns the gene PCA3 and prostate carcinoma.